Time to 10% persistent worsening in 6MWD
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Dmitry Vlodavets, Shiwen Wu, Anna Kostera-Pruszczyk, Jong-Hee Chae, Sheffali Gulati, Jin-Hong Shin, Michelle Lorentzos, Anita Cairns, Yuh-Jyh Jong, Hirofumi Komaki, Jeffrey Statland, Alexandra Prufer de Queiroz Campos Araujo, Juliana Gurgel-Giannetti, Yasuhiro Takeshima, Rosa E Escobar Cedillo, Peter Karachunski, Kazuhiro Haginoya, Vinay Penematsa, Connie Chou, Paula Williams, Christian Werner, Craig M McDonald
J Comp Eff Res 14(10) e240238
Aim: To report the efficacy and safety of ataluren in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) from the phase III, 72-week, placebo-controlled period of Study 041. Materials & methods: Inclusion criteria: boys with nmDMD aged ≥5 years, on a stable corticosteroid regimen for ≥12 months, and baseline 6-minute walk distance (6MWD) ≥150 m. Randomization: 1:1, ataluren (40 mg/kg/day):placebo. Primary end point: slope of 6MWD change (average rate of change). Secondary end points: changes in 6MWD, time to 10% persistent worsening in 6MWD, North Star Ambulatory Assessment score, timed function tests and safety. Study populations: intention-to-treat; patients aged ≥7 to ≤16 years with baseline 6MWD ≥300 m and stand from supine ≥5 s; patients with baseline 6MWD 300-400 m. Results: In the intention-to-treat population (n = 359), over 72 weeks, ataluren reduced the rate of 6MWD decline by 21% (p = 0.0248), reduced the average 6MWD change (p = 0.0248), delayed time to 10% persistent worsening in 6MWD (p = 0.0078), and reduced North Star Ambulatory Assessment total score decline (p = 0.0235), change in 10 m walk/run time (p = 0.0422) and change in time to climb four stairs (p = 0.0293) versus placebo. In the 6MWD 300-400 m subgroup (n = 169), ataluren reduced the rate of 6MWD decline by 30% (p = 0.0310) versus placebo. Ataluren treatment benefits were seen in secondary end points in this subgroup, except for change in time to descend four stairs. In the 6MWD ≥300 m and time to stand from supine ≥5s subgroup (n = 185), there was a 9% slower rate of 6MWD decline for ataluren versus placebo over 72 weeks (p = 0.3626). Ataluren reduced change in time to climb four stairs (p = 0.0179) versus placebo in this subgroup; no treatment benefits were seen for other secondary end points. Ataluren was well tolerated (serious adverse events: ataluren, 7.1%; placebo, 6.8%); no deaths occurred. Conclusion: Long-term ataluren treatment has a favorable benefit-risk profile, slowing motor function decline in the largest phase III nmDMD study to date.
1 个 Figure · 2 个 KM 面板
Figure 2.. Median time to a 10% persistent worsening in 6-minute walk distance. (A) Intention-to-treat population. (B) 6MWD 300–400 m subgroup. Time to a 10% persistent worsening in 6MWD was defined as the last time that 6MWD was not 10% worse than baseline. Patients who did not have a 10% persistent worsening in 6MWD were censored at the time of the last 6MWT during the double-blind period. Owing to COVID-19, some patients’ week 72 visits were delayed and the final data collection for the double-blind period occurred at week 90 or later. 6MWD: 6-minute walk distance; 6MWT: 6-minute walk test; HR: Hazard ratio; ITT: Intention-to-treat.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。